Related Experiment Video

Updated: Jun 4, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics

Reena Philip1, Lea Carrington, Maria Chan

  • 1Division of Immunology and Hematology Devices, Office of In vitro Diagnostic Device Evaluation and Safety Center for Device and Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA. reena.philip@fda.hhs.gov

Bioanalysis
|February 23, 2011
PubMed

Insights

Companion diagnostics enable personalized cancer therapy by targeting specific gene mutations. Developing these tests faces challenges in drug company adoption, clinical validation, and synchronized regulatory review.

Area of Science:

  • Oncology
  • Translational Medicine
  • Biomarker Development

Background:

  • Targeted cancer therapies rely on specific gene mutations.
  • Companion diagnostics are crucial for identifying patients who will benefit from these targeted agents.
  • Personalized medicine aims to tailor treatments based on individual patient profiles.

Purpose of the Study:

  • To outline the challenges in developing companion diagnostics.
  • To discuss the US Food and Drug Administration's (FDA) regulatory approach to companion diagnostics.
  • To highlight the importance of companion diagnostics in modern cancer treatment.

Main Methods:

  • Review of current landscape in targeted cancer therapy and companion diagnostics.
  • Analysis of challenges including industry reluctance, development hurdles, and regulatory synchronization.
  • Examination of the US FDA's regulatory framework for companion diagnostic devices.

Main Results:

  • Companion diagnostics simplify drug discovery and clinical trials.
  • Key challenges include industry buy-in, the complexity of clinical validation, and regulatory hurdles.
  • The FDA is working to synchronize the review of therapeutics and companion diagnostics.

Conclusions:

  • Companion diagnostics are essential for effective personalized cancer therapy.
  • Overcoming development and regulatory challenges is critical for broader adoption.
  • Synchronized regulatory pathways are needed to expedite patient access to targeted treatments.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...